beta-glucans / NFAT Cancer Research Results

B-Gluc, beta-glucans: Click to Expand ⟱
Features:
Beta-glucans are polysaccharides found in the cell walls of certain fungi, bacteria, and plants.
• Enhanced anti-tumor activity: Beta-glucans have been shown to stimulate the immune system, increasing the production of cytokines and activating natural killer cells, which can help to destroy cancer cells.
• Improved survival rates:
• Increased expression of tumor suppressor genes:
• Inhibition of cancer cell proliferation:
• Enhanced chemotherapy efficacy:
• Reduced cancer recurrence:

beta-glucans — Beta-glucans are structurally diverse glucose polymers, most commonly β-(1→3)/(1→6)-linked fungal or yeast polysaccharides and β-(1→3)/(1→4)-linked cereal polysaccharides, that function primarily as innate immune response modifiers rather than conventional directly cytotoxic small molecules. They are best classified as immunomodulatory polysaccharides / biological response modifiers, with common abbreviations including β-glucan, BG, and for specific products lentinan or LNT. Their biological activity is highly source-, branching-, solubility-, and particle-size-dependent, which is a major reason why “beta-glucans” should be treated as a family rather than a single interchangeable agent. In oncology, the strongest evidence base is for adjunctive use of selected fungal β-glucans, especially lentinan-based regimens in East Asian practice, rather than for broad standalone anticancer efficacy.

Primary mechanisms (ranked):

  1. Dectin-1 and related pattern-recognition receptor engagement on macrophages, dendritic cells, monocytes, and neutrophils, driving innate immune activation and antigen-presentation programs.
  2. CR3-mediated enhancement of opsonic tumor cell killing, especially as an adjunct to antibody- or complement-dependent antitumor immunity.
  3. Trained immunity induction with myeloid metabolic and epigenetic reprogramming, increasing later antitumor responsiveness.
  4. Tumor microenvironment remodeling through cytokine and effector-cell shifts, including macrophage, NK-cell, and T-cell support.
  5. Gut-immune axis modulation after oral intake, with luminal and mucosal signaling likely more important than high systemic exposure.
  6. Direct cancer-cell ROS, apoptosis, MAPK, PI3K/Akt, or telomerase effects in some models, but these are product-specific and usually secondary to the immune mechanism.

Bioavailability / PK relevance: Oral beta-glucans are generally poorly digested and have limited measurable systemic absorption; clinical activity after oral dosing is thought to depend mainly on gut-associated immune signaling and downstream myeloid activation. Injectable purified fungal preparations such as lentinan bypass part of this delivery constraint and are more relevant to oncology translation.

In-vitro vs systemic exposure relevance: Many direct tumor-cell effects reported in vitro use purified products and exposure conditions that are not easily mapped to achievable systemic concentrations after oral supplementation. For most oral products, the clinically relevant mechanism is not high free plasma exposure but immune-cell and mucosal engagement.

Clinical evidence status: Adjunctive human evidence exists, strongest for selected purified fungal β-glucans such as lentinan combined with chemotherapy in gastric cancer, but the class as a whole remains heterogeneous and is not established as a standalone anticancer therapy. Overall evidence level: preclinical to small/moderate human adjunctive, with limited high-quality modern global RCT standardization.

reference summaries describe about 2–10 mg IV lentinan weekly as the general adjunctive range used in Japan with chemotherapy.

In general, bigger size and more complex β-glucans such as those derived from Ganoderma lucidum have higher immunomodulating potency.
Lentinan(LNT) are macromolecules with a β-1,3-D-glucan and its unique molecular structure is closely related to its pharmacological activity, and the glucan of the β-glycosidic bond is the key structure for its antitumor function.
Beta-glucans are not one thing. Cancer relevance depends more on source, linkage pattern, branching, solubility, and molecular weight/conformation than on the name alone. The table below is a practical comparison of the main beta-glucan families, with effectiveness interpreted as the strength of anticancer evidence, not a direct potency score.
Beta-glucan type / example Typical source Main linkage pattern Approx. molecular weight Form / PK relevance Cancer evidence / effectiveness
Lentinan Shiitake mushroom (Lentinula edodes) Mostly β-(1→3) backbone with β-(1→6) branches High MW; commonly reported in the ~400–800 kDa range, but varies by preparation Purified fungal polysaccharide; oncology relevance is mainly immune adjuvant, often not dependent on high free plasma exposure Strongest human adjunct evidence; best evidence is in gastric cancer combined with chemotherapy
PSK (Polysaccharide-K, Krestin) Turkey tail mushroom (Trametes versicolor / Coriolus versicolor) Protein-bound fungal β-glucan-rich polysaccharide complex Usually described as high MW; exact reported values vary by product and literature Oral adjuvant immunotherapy product used historically in Japan Strong human adjunct evidence, especially in gastrointestinal cancers
PSP (Polysaccharopeptide) Turkey tail mushroom (Trametes versicolor) Protein-bound mushroom polysaccharopeptide with β-glucan content ~100 kDa Oral immunomodulatory mushroom extract Moderate human evidence; weaker and less standardized than PSK/lentinan
Schizophyllan (SPG) Schizophyllum commune mushroom β-(1→3) backbone with β-(1→6) branches; often triple-helix Very high MW in classic material; some reports around 4,100 kDa, though lower-MW products also exist Purified fungal immunomodulator; conformation matters strongly Moderate human / adjunct relevance; strong mechanistic rationale, less prominent clinical base than lentinan or PSK
Yeast soluble / particulate β-glucans Baker’s yeast (Saccharomyces cerevisiae) Mainly β-(1→3)/(1→6) Highly product-dependent; can range from low-kDa soluble fragments to large particulate material Oral or investigational adjunct; key action is Dectin-1 / CR3 priming and enhancement of antibody/complement-mediated killing Moderate but mostly early-stage evidence; strong preclinical rationale, limited human adjunct evidence
Oat β-glucan Oat bran / oat endosperm Mixed-linkage β-(1→3)/(1→4) Broad range; low-MW preparations may be tens of kDa, while native oat β-glucans can be hundreds of kDa Mainly dietary fiber; oral action is dominated by gut/luminal effects Preclinical only for direct anticancer claims; no comparable human cancer-treatment evidence to fungal products
Barley β-glucan Barley grain Mixed-linkage β-(1→3)/(1→4) Very variable; examples include ~177 kDa native material and experimental low-MW fractions such as ~2 kDa Dietary fiber / functional food ingredient; oral activity mainly gut-mediated Preclinical / mechanistic only; no strong clinical oncology evidence comparable with mushroom BRMs
Other mushroom β-glucans (grifolan, scleroglucan, related fungal glucans) Various fungi / mushrooms Usually β-(1→3) with variable β-(1→6) branching Often high MW, but highly extraction-dependent Mostly research or regional adjunct products Promising but heterogeneous; usually mechanistic, animal, or limited clinical adjunct data

Mechanistic matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Dectin-1 innate immune sensing Indirect ↓ immune escape Macrophages/DCs/monocytes ↑ activation R/G Innate immune priming Core class mechanism for fungal and yeast β-glucans; antitumor effect is mainly host-mediated rather than direct tumor poisoning.
2 CR3 complement-assisted tumor killing ↓ survival of opsonized tumor cells Neutrophils/monocytes ↑ cytotoxic response R/G Effector-cell mediated tumor killing Most relevant when tumor cells are complement-opsonized or when combined with antibody-based therapy.
3 Trained immunity myeloid reprogramming Indirect ↓ tumor progression and metastasis ↑ durable innate responsiveness G Longer-horizon antitumor conditioning Supported by recent mechanistic literature; involves metabolic and epigenetic rewiring rather than an acute cytotoxic hit.
4 NK cell and Th1 cytokine support Indirect ↓ tumor persistence NK activity ↑, IFN-γ ↑, phagocytosis ↑ R/G Immune amplification Frequently observed downstream effect; helps explain adjunctive synergy with chemo- or immunotherapy in some settings.
5 Tumor microenvironment inflammatory remodeling ↓ immunosuppressive tone (context-dependent) Myeloid signaling ↑/↔ (context-dependent) G TME repolarization Can improve antigen presentation and effector recruitment, but inflammatory readouts vary by product, model, and tumor context.
6 PI3K/Akt and MAPK signaling ↓/↔ (context-dependent) ↔/↑ immune-cell signaling R/G Contextual intracellular signaling modulation Tumor-cell inhibition is reported for some purified products, but this is not a uniform class effect and should be treated as secondary.
7 Mitochondrial ROS increase (secondary) ↑ ROS (high concentration only) or ↔ ↔ P/R Contextual apoptosis support Direct ROS-mediated tumor stress appears in some in-vitro systems, but is not the dominant translational mechanism for oral beta-glucans.
8 BAX / Bcl-2 apoptotic balance BAX ↑, Bcl-2 ↓ (model-dependent) ↔ R/G Pro-apoptotic tilt Usually reported with selected purified fungal preparations; likely downstream of immune or stress signaling rather than universally primary.
9 Gut-immune axis Indirect ↓ tumor-supportive inflammation Mucosal immunity ↑, microbiota modulation ↑ G Oral delivery relevance Especially important for oral products because luminal persistence and mucosal interaction are more plausible than high systemic exposure.
10 Radiosensitization or Chemosensitization ↑ response to therapy (context-dependent) Potential toxicity buffering ↑/↔ G Adjunctive therapeutic leverage Best human signal is as an adjunct, especially lentinan plus chemotherapy in gastric cancer; effect is product- and regimen-specific.
11 Clinical Translation Constraint Heterogeneous direct efficacy Generally tolerated G Translation limit Major constraints are structural heterogeneity, source dependence, poor oral systemic exposure, variable manufacturing, and overgeneralization from “beta-glucan” as a single entity.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
NFAT, nuclear factor of activated T cells: Click to Expand ⟱
Source:
Type:
NFAT is a family of transcription factors that play a crucial role in the regulation of gene expression in various cell types, including immune cells and cancer cells. NFAT proteins are involved in the regulation of cell growth, differentiation, and survival, and their dysregulation has been implicated in the development and progression of cancer.
NFAT family: NFAT1, NFAT2, NFAT3, NFAT4, and NFAT5.
Cell proliferation: NFAT proteins can regulate the expression of genes involved in cell cycle progression and cell growth, which can contribute to the development of cancer.
• Angiogenesis: NFAT proteins have been implicated in the regulation of angiogenesis, the process of new blood vessel formation, which is essential for tumor growth and metastasis.
• Metastasis: NFAT proteins can regulate the expression of genes involved in cell migration and invasion, which can contribute to the development of metastatic disease.
• Immune evasion: NFAT proteins can regulate the expression of genes involved in immune evasion, which can allow cancer cells to evade the immune system.

Studies have shown that NFAT proteins are overexpressed in several types of cancer, including breast, lung, and colon cancer.
Scientific Papers found: Click to Expand⟱
874- B-Gluc,    Potential promising anticancer applications of β-glucans: a review
- Review, NA, NA
AntiCan↑, TumCG↓, BAX↑, Bcl-2↓, IFN-γ↑, PI3K/Akt↑, MAPK↑, NFAT↑, NF-kB↑, ROS↑, NK cell↑, TumCCA↑, ERK↓, Telomerase↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

PI3K/Akt↑, 1,  

Cell Death ⓘ

BAX↑, 1,   Bcl-2↓, 1,   MAPK↑, 1,   Telomerase↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   TumCG↓, 1,  

Migration ⓘ

NFAT↑, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↑, 1,   NF-kB↑, 1,   NK cell↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: NFAT, nuclear factor of activated T cells
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:245  Target#:586  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page